title: Group A Streptococcus Toxic Shock Syndrome: An outbreak report and review of the literature.
abstract: Group A Streptococcal (GAS) Toxic Shock Syndrome (TSS) is an acute, rapidly progressive, and often fatal illness. Outbreaks can occur in hospitals. However, early infection control measures may interrupt transmissions and prevent morbidity and mortality. Two cases of invasive GAS TSS were diagnosed within 48h after two uncomplicated laparoscopic surgeries that were performed in the same operating room of a women's hospital. Investigations conducted by the infection prevention and control department of the hospital identified 46 obstetrical staff members who were involved in the surgeries and/or had contact with either of the patients. All of the staff members were interviewed regarding any recent history of upper respiratory tract infections, the presence of skin lesions and vaginal or rectal symptoms. Throat, rectal, and vaginal cultures were obtained two times from all of the involved staff members. Throat colonization with GAS was detected in the cultures from one obstetrical intern who attended the 1st surgery and from one nurse who had formerly worked in the postnatal ward. These two strains were epidemiologically different from each other and from the outbreak strain. Both carriers were suspended from direct patient care and were treated with a ten-day course of oral clindamycin. The success of their decolonization status was assessed at the end of therapy and at three, six, nine and twelve months thereafter before reassigning them to routine work. Unfortunately, in spite of the extensive investigation of all involved personnel and of the environment, the mode of transmission to the second patient could not be established. However, droplet or airborne transmission could not be ruled out. Early and meticulous implementation of infection control measures was crucial and instrumental in the successful management and control of this outbreak. Furthermore, there were no subsequent GAS cases detected during the 24 months following the outbreak.
authors.affiliation: Hamad Medical Corporation, Doha, Qatar.
authors.forename: Jameela Alkhowaiter
authors.initials: JA
authors.lastname: Al-ajmi
authors.forename: Peter
authors.initials: P
authors.lastname: Hill
authors.forename: Carol
authors.initials: C
authors.lastname: O' Boyle
authors.forename: Ma Leni Basco
authors.initials: ML
authors.lastname: Garcia
authors.forename: Manal
authors.initials: M
authors.lastname: Malkawi
authors.forename: Ancy
authors.initials: A
authors.lastname: George
authors.forename: Fatma
authors.initials: F
authors.lastname: Saleh
authors.forename: Bency
authors.initials: B
authors.lastname: Lukose
authors.forename: Badriya Al
authors.initials: BA
authors.lastname: Ali
authors.forename: Mamoun
authors.initials: M
authors.lastname: Elsheikh
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002981:Clindamycin / Q000627:therapeutic use; D003428:Cross Infection / Q000382:microbiology; D004196:Disease Outbreaks; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D011183:Postoperative Complications; D058994:Salpingectomy; D012772:Shock, Septic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D013246:Sterilization, Tubal; D013290:Streptococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000302:isolation & purification*
chemical_list: D000900:Anti-Bacterial Agents; D002981:Clindamycin